Petar Jelinic

Merck & Co., Inc., Rahway, NJ, USA (United States)

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146”.

Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-007929

N/A

0.783DataRank · unranked

19 citations

Matthew H. Taylor, Carol Aghajanian, Allen Lee Cohn, Marcia S. Brose, Christopher Di Simone +12 more